REHOVOT, Israel, Feb. 13, 2017 -- Evogene Ltd. (NASDAQ:EVGN) (TASE:EVGN), a leading biotechnology company for the improvement of crop productivity, announced today that it will release its financial results for the fourth quarter and full year 2016 on Monday, February 27, 2017.
On the day of the announcement, the Company’s management will host a conference call to discuss the results at 09:00 AM Eastern time, 16:00 Israel time. To access the conference call, please dial 1-888-407-2553 toll free from the United States, or +972-3-918-0610 internationally. Access to the call will also be available via live webcast through the Company’s website at www.evogene.com.
A replay of the conference call will be available approximately three hours following the completion of the call. To access the replay, please dial 1-888-782-4291 toll free from the United States, or +972-3-925-5901 internationally. The replay will be accessible through March 1, 2017, and an archive of the webcast will be available on the Company’s website through March 10, 2017.
About Evogene Ltd.:
Evogene (NASDAQ:EVGN) (TASE:EVGN) is a leading biotechnology company for the improvement of crop productivity for the food, feed and fuel industries. The Company operates in three key market segments: improved seed traits (addressing yield and resistance to diseases and environmental stresses); innovative ag-chemicals (developing novel herbicide solutions for weed control); and ag-biologicals. Evogene has collaborations with world-leading seed and ag-chemical companies. For more information, please visit www.evogene.com or contact the Company at [email protected].
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", “expects”, "intends", “anticipates”, “plans”, “believes”, “scheduled”, “estimates” or words of similar meaning. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which beyond Evogene's control, including, without limitation, those risk factors contained in Evogene’s reports filed with the appropriate securities authority. Evogene disclaims any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Contact: Karen Mazor, Director Investor Relations E: [email protected] T: +972 54 228 8039


Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs
Chinese Cars in Europe: Consumer Trust Is Shifting Fast
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy
Bill Ackman Eyes New Fund to Bet Against Market Complacency
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home
SanDisk Joins Nasdaq-100, Replacing Atlassian on April 20
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 



